Changes in Beneficial Ownership · 4
Phio Pharmaceuticals Corp.
PHIONASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-11-09
- Issuer
- Phio Pharmaceuticals Corp.
- Issuer CIK
- 0001533040
- Trading symbol
- PHIO
Reporting owner 1
- Name
- Bitterman Robert J
- Reporting owner CIK
- 0001304395
- Relationship
- Director · Officer
- Officer title
- Chairman, Pres. & CEO
- Address
- C/O PHIO PHARMACEUTICALS CORP., 411 SWEDELAND RD., STE 23-1080, KING OF PRUSSIA, PA, 19406
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock, $.0001 par value | 2026-11-09 | P · Form 4 | 25,000 | A | 0.82 | 789,871[F1] | D |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Includes shares of common stock underlying unvested restricted stock units.↩ 1
Signature 1
- Signed
- /s/ Lisa C. Carson, Attorney-in-fact
- Date
- 2026-11-10
Company context
Phio (“Phio”, “we”, “our”, or the “Company”) is a clinical stage biotechnology company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future.